OTC · EBRCZ
Healthcare · Medical - Specialties
$0.11
Up+$0.00 (+0.00%)
Updated Oct 24, 2026, 10:37 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · EBRCZ
1M range · 0 trading sessions · Daily adjusted prices
EBRCZ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning EBRCZ.
Company
Market Activity
Research & News
EBRCZ research
Company profile and research snapshot.
EBR SYS INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 30, 2026 | E&P | Buy | — |
| Aug 24, 2026 | CANACCORD GENUITY | Buy | — |
| Aug 2, 2026 | BELL POTTER SECURITIES | Buy | — |
| Jul 14, 2026 | BELL POTTER SECURITIES | Buy | — |
| Jul 13, 2026 | BELL POTTER SECURITIES | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 20, 2026
SUNNYVALE, Calif., October 20, 2026--EBR Systems, Inc., developer of the world’s only left ventricular endocardial pacing (LVEP) system for heart failure, announces the appointment of Robert C. Canby, MD, as Chief Medical Officer.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EBRCZ.
